Kuvan (Sapropterin Dihydrochloride) Patent Expiration, LOE Window & CMS Spending

Kuvan (Sapropterin Dihydrochloride) by BioMarin Pharmaceutical: FDA Orange Book LOE 2026-05-16, 5 AB generics, $24.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBioMarin Pharmaceutical
FDA Application & PathwayN022181 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-05-16
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$24.5M
2024 Medicare Part D Spend$3.5M
2024 Medicaid Spend$21.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.